Xeris Biopharma Holdings Inc
XERS5.560USD
+0.180+3.35%
收盤 08/04, 16:00（美東）報價延遲15分鐘
867.44M總市值
虧損本益比TTM
關於 Xeris Biopharma Holdings Inc 公司
Xeris Biopharma Holdings, Inc. 是一家生物製藥公司，致力於通過開發和商業化一系列治療產品來改善患者的生活。該公司有三種商業產品。Gvoke 是一種即用型液體穩定型胰高血糖素，用於治療嚴重低血糖症。Recorlev 是一種皮質醇合成抑制劑，獲准用於治療無法進行手術或無法治癒的庫欣綜合徵成年患者的內源性皮質醇增多症。Keveyis 是美國首個獲批用於治療高鉀血癥、低鉀血癥和原發性週期性麻痹 (PPP) 相關變體的療法。該公司還擁有一系列開發項目，利用其專有的配方科學 XeriSol 和 XeriJect 推出新產品。其候選產品 XP-8121 旨在每週注射一次，小劑量，皮下注射，繞過胃腸道，可以避免許多治療併發症。
公司簡介
公司代碼XERS
公司名稱Xeris Biopharma Holdings Inc
上市日期Jun 21, 2018
CEOMr. John P. Shannon
員工數量394
證券類型Ordinary Share
年結日Jun 21
公司地址1375 West Fulton Street, Suite 1300
城市CHICAGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編60607
電話18444455704
網址https://www.xerispharma.com/
公司代碼XERS
上市日期Jun 21, 2018
CEOMr. John P. Shannon
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
937.75K
+2.74%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
513.93K
+80.45%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
169.78K
+41.74%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
164.14K
+43.80%
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
113.87K
+78.28%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
112.91K
+79.48%
Mr. Steven M. Pieper
Mr. Steven M. Pieper
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James Brady
Mr. James Brady
Independent Director
Independent Director
--
--
Mr. John P. Shannon
Mr. John P. Shannon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Allison Wey
Ms. Allison Wey
Senior Vice President - Investor Relations & Corporate Communications
Senior Vice President - Investor Relations & Corporate Communications
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
937.75K
+2.74%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
513.93K
+80.45%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
169.78K
+41.74%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
164.14K
+43.80%
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
113.87K
+78.28%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
112.91K
+79.48%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
業務USD
名稱
營收
佔比
Product revenue -Recorlev
25.53M
42.47%
Product revenue - Gvoke
20.84M
34.67%
Product revenue - Keveyis
11.43M
19.01%
Royalty, contract and other revenue
2.32M
3.85%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Product revenue -Recorlev
25.53M
42.47%
Product revenue - Gvoke
20.84M
34.67%
Product revenue - Keveyis
11.43M
19.01%
Royalty, contract and other revenue
2.32M
3.85%
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
5.99%
The Vanguard Group, Inc.
5.06%
Geode Capital Management, L.L.C.
2.13%
State Street Global Advisors (US)
2.08%
Morgan Stanley & Co. LLC
1.96%
Other
82.78%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
5.99%
The Vanguard Group, Inc.
5.06%
Geode Capital Management, L.L.C.
2.13%
State Street Global Advisors (US)
2.08%
Morgan Stanley & Co. LLC
1.96%
Other
82.78%
股東類型
持股股東
佔比
Investment Advisor
20.15%
Investment Advisor/Hedge Fund
13.83%
Hedge Fund
13.12%
Research Firm
6.70%
Individual Investor
4.21%
Pension Fund
0.27%
Venture Capital
0.14%
Family Office
0.10%
Bank and Trust
0.09%
Other
41.41%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
335
93.79M
58.56%
+12.75M
2025Q1
335
93.86M
58.93%
+12.36M
2024Q4
297
71.87M
48.21%
-8.26M
2024Q3
280
71.79M
48.23%
-5.89M
2024Q2
269
66.65M
44.99%
-10.81M
2024Q1
284
69.70M
49.68%
-4.28M
2023Q4
271
65.59M
47.45%
-7.22M
2023Q3
264
62.48M
45.27%
-15.54M
2023Q2
276
65.86M
49.56%
-15.25M
2023Q1
284
62.09M
46.86%
-20.83M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
9.59M
5.99%
-94.01K
-0.97%
Mar 31, 2025
The Vanguard Group, Inc.
8.11M
5.06%
+210.58K
+2.67%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.41M
2.13%
+54.40K
+1.62%
Mar 31, 2025
State Street Global Advisors (US)
3.33M
2.08%
-16.62K
-0.50%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.15M
1.96%
+2.62M
+494.91%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.05M
1.91%
+1.69M
+123.87%
Mar 31, 2025
Rosalind Advisors, Inc.
2.50M
1.56%
-609.01K
-19.61%
Mar 31, 2025
Millennium Management LLC
2.32M
1.45%
+369.42K
+18.96%
Mar 31, 2025
Nuveen LLC
2.22M
1.39%
+324.06K
+17.07%
Mar 31, 2025
Goldman Sachs & Company, Inc.
2.20M
1.37%
+1.12M
+103.68%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Virtus LifeSci Biotech Clinical Trials ETF
0.95%
iShares Micro-Cap ETF
0.16%
Federated Hermes MDT Small Cap Core ETF
0.14%
Principal U.S. Small-Cap ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.06%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.38%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.95%
iShares Micro-Cap ETF
佔比0.16%
Federated Hermes MDT Small Cap Core ETF
佔比0.14%
Principal U.S. Small-Cap ETF
佔比0.09%
ProShares Ultra Nasdaq Biotechnology
佔比0.08%
Invesco Nasdaq Biotechnology ETF
佔比0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.07%
Fidelity Enhanced Small Cap ETF
佔比0.06%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
